出血创伤患者早期同时使用冷沉淀与血浆相比单用血浆的临床获益
该回顾性队列研究基于美国外科医师学会创伤质量改进项目(TQIP)2015至2019年数据库,纳入入院4小时内接受≥5单位浓缩红细胞且至少1单位新鲜冰冻血浆的出血创伤患者,按入院4小时内是否使用冷沉淀二分为冷沉淀+血浆组与单用血浆组。经倾向性评分匹配生成4852对,凝血因子剂量已平衡;冷沉淀+血浆组院内死亡1959例(40.4%)vs 单用血浆组2142例(44.1%),OR 0.86(95%CI 0.79-0.93);不良事件发生率1857例(38.3%)vs 1875例(38.6%),OR 1.02(95%CI 0.94-1.10),无显著差异。多项敏感性分析结果相似。作者结论认为冷沉淀联合血浆与出血创伤患者死亡率降低显著相关,并认为需未来随机对照试验确认。
要点
- 出血创伤患者入院4小时内同时使用冷沉淀+血浆较单用血浆院内死亡率更低:40.4% vs 44.1%,OR 0.86(95%CI 0.79-0.93)。
- 冷沉淀+血浆组与单用血浆组不良事件发生率无显著差异:38.3% vs 38.6%,OR 1.02(95%CI 0.94-1.10)。
- 纳入标准为入院4小时内接受≥5单位浓缩红细胞且至少1单位新鲜冰冻血浆的出血创伤患者。
- 研究采用倾向性评分匹配分析,匹配后两组凝血因子给药剂量已平衡,共生成4852对匹配。
- 多项敏感性分析结果与主要分析相似,作者认为需未来随机对照试验确认。
适用人群与场景
- 出血创伤患者,需在入院4小时内接受≥5单位浓缩红细胞且至少1单位新鲜冰冻血浆。
- 数据来源为美国外科医师学会创伤质量改进项目(TQIP)数据库2015至2019年。
诊断标准与关键阈值
- 纳入标准:入院4小时内接受≥5单位浓缩红细胞且至少1单位新鲜冰冻血浆。
- 分组依据:入院4小时内是否使用冷沉淀,分为冷沉淀+血浆组与单用血浆组。
研究设计与关键结果
- 研究类型:回顾性队列研究,基于美国外科医师学会创伤质量改进项目数据库2015至2019年。
- 共24002例符合分析(冷沉淀+血浆组6018例,单用血浆组17984例),经倾向性评分匹配生成4852对。
- 主要终点院内死亡率:冷沉淀+血浆组1959例(40.4%)vs 单用血浆组2142例(44.1%),OR 0.86(95%CI 0.79-0.93)。
- 次要终点不良事件发生率:冷沉淀+血浆组1857例(38.3%)vs 单用血浆组1875例(38.6%),OR 1.02(95%CI 0.94-1.10),无显著差异。
- 多项敏感性分析显示相似结果。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性;作者结论指出需未来随机对照试验确认这些结果。
对床旁实践的改变
- 作者认为,冷沉淀联合血浆与出血创伤患者死亡率降低显著相关,需未来随机对照试验确认。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The effectiveness of cryoprecipitate (Cryo) in trauma has not been well established; the benefits of Cryo might have been overestimated in previous studies since the difference in the total amount of administered clotting factors was not considered. We aimed to evaluate the benefits of the concurrent use of Cryo in combination with fresh frozen plasma (FFP) for bleeding trauma patients.
DESIGN: Retrospective cohort study.
SETTING: The American College of Surgeons Trauma Quality Improvement Program database between 2015 and 2019.
PATIENTS: Patients who received greater than or equal to 5 units of packed RBCs and at least 1 unit of FFP within the first 4 hours after arrival to a hospital were included and dichotomized according to whether Cryo was used within the first 4 hours of hospital arrival.
MEASUREMENTS AND MAIN RESULTS: The outcomes of patients treated with Cryo and FFP were compared with those treated with FFP only using propensity score-matching analysis. The dose of administered clotting factors in each group was balanced. The primary outcome was inhospital mortality, and the secondary outcome was the occurrence rate of adverse events. A total of 24,002 patients (Cryo+FFP group: 6,018; FFP only group: 17,984) were eligible for analysis, of whom 4,852 propensity score-matched pairs were generated. Significantly lower inhospital mortality (1,959 patients [40.4%] in the Cryo+FFP group vs 2,142 patients [44.1%] in the FFP only group; odds ratio [OR], 0.86; 95% CI, 0.79-0.93) was observed in the Cryo+FFP group; no significant difference was observed in the occurrence rate of adverse events (1,857 [38.3%] vs 1,875 [38.6%]; OR, 1.02; 95% CI, 0.94-1.10). Several sensitivity analyses showed similar results.
CONCLUSIONS: Cryo use combined with FFP was significantly associated with reduced mortality in bleeding trauma patients. Future randomized controlled trials are warranted to confirm these results.
参考来源
- Endo A, Senda A, Otomo Y, et al. Clinical Benefits of Early Concurrent Use of Cryoprecipitate and Plasma Compared With Plasma Only in Bleeding Trauma Patients. Crit Care Med. 2022. PMID: 35759689. doi:10.1097/CCM.0000000000005596
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。